Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.

[1]  A. Vetuschi,et al.  Localization of αυβ6 Integrin-TGF-β1/Smad3, mTOR and PPARγ in Experimental Colorectal Fibrosis , 2013, European journal of histochemistry : EJH.

[2]  G. Rogler,et al.  A New Heterotopic Transplant Animal Model of Intestinal Fibrosis , 2013, Inflammatory bowel diseases.

[3]  Dan Knights,et al.  Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome , 2013, Gut.

[4]  S. Hubchak,et al.  TGF-β/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1α expression. , 2013, American journal of physiology. Renal physiology.

[5]  E. Nimmo,et al.  Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics , 2013, Gastroenterology.

[6]  P. Rutgeerts,et al.  Unique Gene Expression and MR T2 Relaxometry Patterns Define Chronic Murine Dextran Sodium Sulphate Colitis as a Model for Connective Tissue Changes in Human Crohn’s Disease , 2013, PloS one.

[7]  F. Rieder.  The Gut Microbiome in Intestinal Fibrosis: Environmental Protector or Provocateur? , 2013, Science Translational Medicine.

[8]  B. Coombes,et al.  Persistent infection with Crohn’s disease-associated adherent-invasive Escherichia coli leads to chronic inflammation and intestinal fibrosis , 2013, Nature Communications.

[9]  Youhua Liu,et al.  Loss of Klotho contributes to kidney injury by derepression of Wnt/β-catenin signaling. , 2013, Journal of the American Society of Nephrology : JASN.

[10]  A. Vetuschi,et al.  Can we prevent, reduce or reverse intestinal fibrosis in IBD? , 2013, European review for medical and pharmacological sciences.

[11]  M. Lucarelli,et al.  Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Allelic Variants Relate to Shifts in Faecal Microbiota of Cystic Fibrosis Patients , 2013, PloS one.

[12]  A. Vetuschi,et al.  P056 GED-0507–34 Levo, a novel modulator of PPARgamma as new therapeutic strategy in the treatment of intestinal fibrosis , 2013 .

[13]  P. Angus,et al.  Advanced glycation end products augment experimental hepatic fibrosis , 2013, Journal of gastroenterology and hepatology.

[14]  A. Gandelli,et al.  P054 In experimental model of colitis the therapeutic efficacy of mesenchymal stem cells is not gut-homing dependent but is mediated at distance by secretion of TNF-alfa stimulated gene/protein 6 , 2013 .

[15]  M. Petroni,et al.  The role of adipose tissue-associated macrophages and T lymphocytes in the pathogenesis of inflammatory bowel disease. , 2013, Cytokine.

[16]  J. González,et al.  Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project , 2012, Gut.

[17]  A. Fabre,et al.  The hedgehog system machinery controls transforming growth factor-β-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis. , 2012, The American journal of pathology.

[18]  Junli Guo,et al.  Inhibition of Notch Signaling by a γ-Secretase Inhibitor Attenuates Hepatic Fibrosis in Rats , 2012, PloS one.

[19]  M. Sans,et al.  Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[20]  C. Pothoulakis,et al.  Adipose Tissue and Inflammatory Bowel Disease Pathogenesis , 2012, Inflammatory bowel diseases.

[21]  X. Chen,et al.  Identification of Disease-Associated DNA Methylation in B Cells from Crohn’s Disease and Ulcerative Colitis Patients , 2012, Digestive Diseases and Sciences.

[22]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[23]  M. Kuro-o.  Klotho in health and disease , 2012, Current opinion in nephrology and hypertension.

[24]  S. Qiu,et al.  Significance of the Balance between Regulatory T (Treg) and T Helper 17 (Th17) Cells during Hepatitis B Virus Related Liver Fibrosis , 2012, PloS one.

[25]  J. Mertz,et al.  Reversal of transforming growth factor-β induced epithelial-to-mesenchymal transition and the ZEB proteins , 2012, Fibrogenesis & tissue repair.

[26]  Z. Tulassay,et al.  The Impact of Matrix Metalloproteinases and Their Tissue Inhibitors in Inflammatory Bowel Diseases , 2012, Digestive Diseases.

[27]  C. Loddenkemper,et al.  Mesenteric fat—control site for bacterial translocation in colitis? , 2012, Mucosal Immunology.

[28]  M. Zeitz,et al.  Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn's disease , 2012, Gut.

[29]  Miquel Sans,et al.  Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing. , 2012, Journal of Crohn's & colitis.

[30]  Oliver Distler,et al.  Basic and translational research , 2011 .

[31]  Feng Zhang,et al.  Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis. , 2012, Cellular signalling.

[32]  J. Schulzke,et al.  Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics , 2012, The Journal of physiology.

[33]  Philippe Chavatte,et al.  Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. , 2012, Journal of medicinal chemistry.

[34]  S. Naser,et al.  Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis. , 2012, World journal of gastroenterology.

[35]  B. Bertin,et al.  Visceral fat and gut inflammation. , 2012, Nutrition.

[36]  E. Seki,et al.  Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut , 2012, The Journal of physiology.

[37]  Yingwei Chen,et al.  miR-200b is involved in intestinal fibrosis of Crohn’s disease , 2012, International journal of molecular medicine.

[38]  J. Pekow,et al.  MicroRNAs in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[39]  Oliver Distler,et al.  Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis , 2012, Nature Communications.

[40]  G. Węgrzyn,et al.  Clinical parameters of inflammatory bowel disease in children do not correlate with four common polymorphisms of the transforming growth factor β1 gene. , 2011, Acta biochimica Polonica.

[41]  K. Ley,et al.  SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis. , 2011, Inflammatory bowel diseases.

[42]  C. Hofmann,et al.  C1q/TNF‐related protein‐3 (CTRP‐3) is secreted by visceral adipose tissue and exerts antiinflammatory and antifibrotic effects in primary human colonic fibroblasts , 2011, Inflammatory bowel diseases.

[43]  S. Violette,et al.  Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease , 2011, International journal of rheumatology.

[44]  I. Lawrance,et al.  Predictors of fibrostenotic Crohn's disease , 2011, Inflammatory bowel diseases.

[45]  C. Motte.  Hyaluronan in intestinal homeostasis and inflammation: implications for fibrosis. , 2011 .

[46]  F. Marra,et al.  Modulation of Liver Fibrosis by Adipokines , 2011, Digestive Diseases.

[47]  T. Blackwell,et al.  Alveolar Epithelial Cells Undergo Epithelial-to-Mesenchymal Transition in Response to Endoplasmic Reticulum Stress* , 2011, The Journal of Biological Chemistry.

[48]  W. Koltun,et al.  Identification of disease‐associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease , 2011, Clinical genetics.

[49]  E. Morrisey,et al.  Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs , 2011, Proceedings of the National Academy of Sciences.

[50]  M. Ocker,et al.  Role of cannabinoid receptors and RAGE in inflammatory bowel disease. , 2011, Histology and histopathology.

[51]  C. Fiocchi,et al.  Themes in fibrosis and gastrointestinal inflammation. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[52]  M. Nagata,et al.  Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium , 2011, Pathology international.

[53]  P. Higgins,et al.  The Prognostic Power of the NOD2 Genotype for Complicated Crohn's Disease: A Meta-Analysis , 2011, The American Journal of Gastroenterology.

[54]  Jun Yu,et al.  Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice , 2011, Scandinavian journal of gastroenterology.

[55]  S. Danese.  Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: ‘brothers in arms’ , 2011, Gut.

[56]  S. Targan,et al.  Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens , 2011, Inflammatory bowel diseases.

[57]  M. Gessler,et al.  Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. , 2010, The Journal of clinical investigation.

[58]  C. Fiocchi,et al.  192 Pro-Fibrogenic Activity of Toll-Like Receptor (TLR) and NOD-Like Receptor (NLR) Ligands on Human Intestinal Myofibroblasts (HIF) – Linking Bacterial Innate Immunity to Intestinal Fibrosis , 2010 .

[59]  M. Abreu,et al.  Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis , 2010, Innate immunity.

[60]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[61]  A. Sepulveda,et al.  Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis , 2009, Journal of leukocyte biology.

[62]  M. Kapoor,et al.  Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. , 2009, Arthritis and rheumatism.

[63]  T. Cheng,et al.  Activation of peroxisome proliferator-activated receptor-γ inhibits transforming growth factor-β1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro , 2009, Archives of Dermatological Research.

[64]  M. Helmrath,et al.  A new animal model of postsurgical bowel inflammation and fibrosis: the effect of commensal microflora , 2009, Gut.

[65]  A. Smith,et al.  Arginase-1–Expressing Macrophages Suppress Th2 Cytokine–Driven Inflammation and Fibrosis , 2009, PLoS pathogens.

[66]  P. Morel,et al.  Molecular aspects of intestinal radiation-induced fibrosis. , 2009, Current molecular medicine.

[67]  G. Corazza,et al.  Transforming growth factor β signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures , 2009, Gut.

[68]  K. Flanders,et al.  Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid–induced colorectal fibrosis , 2009, European journal of clinical investigation.

[69]  E. Geissler,et al.  IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. , 2008, Gastroenterology.

[70]  Rustam I. Aminov,et al.  Predominant Role of Host Genetics in Controlling the Composition of Gut Microbiota , 2008, PloS one.

[71]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[72]  I. Sobhani,et al.  The V249I polymorphism of the CX3CR1 gene is associated with fibrostenotic disease behavior in patients with Crohn's disease , 2008, European journal of gastroenterology & hepatology.

[73]  I. Lawrance,et al.  Indomethacin and Retinoic Acid Modify Mouse Intestinal Inflammation and Fibrosis: A Role for SPARC , 2008, Digestive Diseases and Sciences.

[74]  B. Finlay,et al.  Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis. , 2008, Gastroenterology.

[75]  T. Berg,et al.  A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. , 2007, Journal of hepatology.

[76]  D. Hommes,et al.  Role of matrix metalloproteinase,tissue inhibitor of metalloproteinase and tumor necrosis factor-α single nucleotide gene polymorphisms in inflammatory bowel disease , 2007 .

[77]  C. Hogaboam,et al.  Infectious disease, the innate immune response, and fibrosis. , 2007, The Journal of clinical investigation.

[78]  C. Tsang,et al.  Targeting mammalian target of rapamycin (mTOR) for health and diseases. , 2007, Drug discovery today.

[79]  G. Radford-Smith,et al.  Angiotensinogen and transforming growth factor β1: novel genes in the pathogenesis of Crohn’s disease , 2006, Journal of Medical Genetics.

[80]  Dakang Xu,et al.  Transforming Growth Factor (cid:1) Suppresses Human Telomerase Reverse Transcriptase (hTERT) by Smad3 Interactions with c-Myc and the hTERT Gene , 2022 .

[81]  M. Radomski,et al.  Role of Matrix Metalloproteinases in Intestinal Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[82]  Philippe Chavatte,et al.  PPARγ as a new therapeutic target in inflammatory bowel diseases , 2006, Gut.

[83]  Martin Paul,et al.  Physiology of local renin-angiotensin systems. , 2006, Physiological reviews.

[84]  S. Brand,et al.  Increased Expression of the Chemokine Fractalkine in Crohn's Disease and Association of the Fractalkine Receptor T280M Polymorphism with a Fibrostenosing Disease Phenotype , 2006, The American Journal of Gastroenterology.

[85]  A. Lacy,et al.  Crohn's Disease Patients Carrying Nod2/CARD15 Gene Variants Have an Increased and Early Need for First Surgery due to Stricturing Disease and Higher Rate of Surgical Recurrence , 2005, Annals of surgery.

[86]  F. Galeazzi,et al.  TGF-β1 gene transfer to the mouse colon leads to intestinal fibrosis , 2005 .

[87]  F. Cominelli,et al.  Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. , 2005, Gastroenterology.

[88]  J. Willis,et al.  A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. , 2003, Gastroenterology.

[89]  T. Keku,et al.  IGF-I and TGF-beta1 have distinct effects on phenotype and proliferation of intestinal fibroblasts. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[90]  J. Watson,et al.  CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells , 1993, The Journal of experimental medicine.

[91]  M. Pines,et al.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. , 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[92]  J. Distler,et al.  Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis , 2012, Archives of Dermatological Research.

[93]  C. Moore,et al.  An alternate perspective on the roles of TIMPs and MMPs in pathology. , 2012, The American journal of pathology.

[94]  A. Kaser,et al.  Endoplasmic reticulum stress and intestinal inflammation , 2010, Mucosal Immunology.

[95]  D. Hommes,et al.  Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. , 2007, World journal of gastroenterology.

[96]  Z. Werb,et al.  Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. , 2007, Physiological reviews.

[97]  P. Morrissey,et al.  CD 4 + T Cells That Express High Levels of CD 45 RB Induce Wasting Disease When Transferred into Congenic Severe Combined Immunodeficient Mice . Disease Development Is Prevented by Cotransfer of Purified CD 4 + T Cells , 2003 .

[98]  J. Willis,et al.  Distinct inflammatory mechanisms mediate early versus late colitis in mice. , 2002, Gastroenterology.